Condevax Bio Co., Ltd.

Founded in China in 2009, CanSino Biologics is committed to providing solutions for the prevention and treatment of infectious diseases around the world. It focuses on the research and development, production and commercialization of innovative, high-quality, and accessible human vaccines. It is an industry-leading high-tech biological products company. CanSino Biologics' mission has always been to "provide innovative, high-quality, accessible vaccines to the world" to achieve its corporate vision of "continuous innovation and a world free of epidemics". The company has listed H shares on the main board of the Hong Kong Stock Exchange (stock code 6185.HK) and A shares on the Shanghai Stock Exchange's Science and Technology Innovation Board (stock code 688185). It is the first "A+H" vaccine stock since the launch of China's Science and Technology Innovation Board. CanSinoBio's marketed products include: Kwisha®, the only single-shot recombinant new coronavirus vaccine (adenovirus type 5 vector) among the new coronavirus vaccines on the market in China, Kwisha® Wuyou® (type 5 adenovirus vector), the world's first inhaled COVID-19 vaccine, and China's first quadrivalent meningococcal conjugate vaccine against ACYW135 group meningococci Polysaccharide conjugate vaccine (CRM197 vector) Menheixin®, China's first bivalent meningitis conjugate vaccine Group A and C meningococcal polysaccharide conjugate vaccine (CRM197 vector) Menexi® using CRM197 vector, and the world's third recombinant Ebola virus disease vaccine (type 5 adenovirus vector) that has entered clinical research and Asia's first. There are also a number of China's best vaccines, China's first vaccines, globally innovative vaccines, and the world's best vaccines in the research and clinical stages. We have five major technology platforms for global innovation, including viruses